Domestic pharma giant Cipla has taken the route of applying for a "voluntary license" for Merck's HIV Isentress (a generic raltegravir) saying it is not reaching needy patients in India and is prices exorbitantly.
first published: Apr 4, 2011 12:50 pm
A collection of the most-viewed Moneycontrol videos.

The Tenant Diwali Special: From Mumbai Slums to Alibaug Villas: 2025 Recap

Nifty Snaps 6-Day Winning Streak As Markets Get In Consolidation Mode| Closing Bell Live

Kenneth Andrade picks three unusual, ignored sectors to bet on in Samvat 2082

Nifty Likely To Consolidate Until It Clears 26,000 Mark Decisively | Opening Bell Live
You are already a Moneycontrol Pro user.

